STEP-1
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is STEP-1?
Semaglutide 2.4 mg weekly against placebo, the pivotal phase 3, run across 1,961 participants carrying excess weight (Wilding et al., NEJM 2021, PMID 33567185).
Average loss reached 14.9% by week 68. Nearly every piece of semaglutide marketing you encounter rests on that figure, compounded products included, though none of those were in the trial.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where STEP-1 comes up on this site
On GLP Watchdog, STEP-1 comes up in 4 tools.
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers